GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » YoY EBITDA Growth

Vaxart (STU:NB11) YoY EBITDA Growth : 52.69% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Vaxart YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Vaxart's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 52.69%.

Vaxart's EBITDA per Share for the three months ended in Sep. 2024 was €-0.04.

Vaxart YoY EBITDA Growth Historical Data

The historical data trend for Vaxart's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart YoY EBITDA Growth Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.62 49.80 -84.71 -57.96 38.58

Vaxart Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.34 42.31 25.95 48.12 52.69

Vaxart YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Vaxart's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.457--0.744)/ | -0.744 |
=38.58 %

Vaxart's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(-0.044--0.093)/ | -0.093 |
=52.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Vaxart's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » YoY EBITDA Growth
Comparable Companies
CYDY MCRB IZTC VTYX ABOS VIGL SEER BDTX PEPG CDTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
VXRT:USA VXRT:Mexico NB11:Germany
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Website
https://www.vaxart.com
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Headlines

No Headlines